Summary by Moomoo AI
EMERY VACCINES CO., LTD. RECENTLY ANNOUNCED THAT IT HAS SUBMITTED A CLINICAL TRIAL PRE-APPLICATION FOR ITS ASPIRATION VACCINE, IN LINE WITH THE COMPANY'S PRODUCT DEVELOPMENT STRATEGY AND MARKS AN IMPORTANT STEP FORWARD IN THE COMPANY'S DEVELOPMENT OF MULTI-VALUED PRODUCTS. The development of the vaccine aims to strengthen the industry position of EME in the domestic category 2 vaccine sector and to promote the sustainable development of its vaccine business. In addition, the company is advancing the development of a quadrivalent vaccine and is expected to start submitting applications for relevant clinical trials in 2024. The quadriplegic vaccine is designed to prevent a variety of diseases and can reduce infant and toddler vaccination rates and improve vaccination adherence. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer of Amy Vaccines, issued this news on March 4, 2024.